Letter to the Editor: Dolutegravir Monotherapy and Body Weight Gain in Antiretroviral Naïve Patients

AIDS Res Hum Retroviruses. 2022 Oct;38(10):771-773. doi: 10.1089/AID.2021.0234. Epub 2022 Aug 3.

Authors

Massimiliano Lanzafame¹, Sebastiano Rizzardo², Emanuela Lattuada³, Dora Luise⁴, Sandro Vento⁵

Affiliations

¹ Department of Specialistic Area, Unit of Infectious Diseases, S. Maria della Misericordia Hospital, Rovigo, Italy.
² Unit of Internal Medicine, S. Maria del Carmine Hospital, Rovereto, Italy.
³ Infectious Diseases Unit, G.B. Rossi University Hospital, Verona, Italy.
⁴ Unit of Infectious Diseases, S. Bortolo Hospital, Vicenza, Italy.
⁵ Faculty of Medicine, University of Puthisastra, Phnom Penh, Cambodia.

PMID: 35815473
DOI: 10.1089/AID.2021.0234

No abstract available

Publication types

Letter

MeSH terms

Anti-HIV Agents* / therapeutic use
Body Weight
HIV Infections* / drug therapy
HIV Integrase Inhibitors* / adverse effects
Heterocyclic Compounds, 3-Ring / adverse effects
Humans
Oxazines / therapeutic use
Pyridones / therapeutic use

Substances

dolutegravir
Heterocyclic Compounds, 3-Ring
Oxazines
Pyridones
HIV Integrase Inhibitors
Anti-HIV Agents